# Supplemental material for:

# INSIGHT 2: A Phase II study of tepotinib plus osimertinib in *MET*-amplified NSCLC and first-line osimertinib resistance

**Table S1. Clinical outcomes with first-, second- and third-generation EGFR TKIs received as first-line therapy in randomized controlled clinical trials of EGFR TKIs in *EGFR*-mutant advanced NSCLC [1–22]**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author/study** | **Patients assessed for efficacy, n** | **ORR** | **Median PFS** | | **Median OS** |
| **Gefitinib (first-generation)** | | | | | |
| Mok 2009, Fukuoka 2011 [1,2] IPASS | 609 | 43% | 5.7 months | 18.8 months | |
| Maemondo 2010, Inoue 2013 [3,4] NEJ002 | 114 | 74% | 10.8 months | 27.7 months | |
| Mitsudomi 2010, Yoshioka 2019 [5,6] WJTOG3405 | 86 | 62% | 9.2 months | 34.9 months | |
| Han 2012 [7] First-SIGNAL | 159 | 55% | 5.8 months | 22.3 months | |
| **Erlotinib (first-generation)** | | | | | |
| Rosell 2012 [8] EURTAC | 86 | 58% | 9.7 months | 19.3 months | |
| Zhou 2011, Zhou 2015 [9,10] OPTIMAL | 82 | 83% | 13.1 months | 22.8 months | |
| Wu 2015 [11] ENSURE | 110 | 63% | 11.0 months | 26.3 months | |
| Yang 2017 [12] CTONG0901 | 128 | 56% | 13.0 months | 22.9 months | |
| **Icotinib (first-generation)** | | | | | |
| Shi 2017 [13] CONVINCE | 148 | NR | 11.2 months | 30.5 months | |
| **Afatinib (second-generation)** | | | | | |
| Sequist 2013, Yang 2015 [14,15] LUX-Lung 3 | 230 | 56% | 11.1 months | 28.2 months | |
| Wu 2014, Yang 2015 [15,16] LUX-Lung 6 | 242 | 67% | 11.0 months | 23.1 months | |
| Park 2016, Paz-Ares 2017 [17,18] LUX-Lung 7 | 160 | 70% | 11.0 months | 27.9 months | |
| **Dacomitinib (second-generation)** | | | | | |
| Wu 2017, Mok 2021 [19,20] ARCHER1050 | 227 | 75% | 14.7 months | 34.1 months | |
| **Osimertinib (third-generation)** | | | | | |
| Soria 2018, Ramalingam 2020 [21,22] FLAURA | 279 | 80% | 18.9 months | 38.6 months | |

EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TKI: tyrosine kinase inhibitor.

# References for supplemental material

1. Mok TS *et al*. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N. Engl. J. Med*. 361(10), 947–957 (2009).
2. Fukuoka M *et al*. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J. Clin. Oncol*. 29(21), 2866–2874 (2011).
3. Maemondo M *et al*. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N. Engl. J. Med*. 362(25), 2380–2388 (2010).
4. Inoue A *et al*. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann. Oncol*. 24(1), 54–59 (2013).
5. Mitsudomi T *et al*. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol*. 11(2), 121–128 (2010).
6. Yoshioka H *et al*. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. *Ann. Oncol*. 30(12), 1978–1984 (2019).
7. Han J-Y *et al*. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.  *J. Clin. Oncol*. 30(10), 1122–1128 (2012).
8. Rosell R *et al*. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 13(3), 239–246 (2012)
9. Zhou C *et al*. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 12(8), 735–742 (2011).
10. Zhou C *et al*. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). *Ann. Oncol*. 26(9), 1877–1883 (2015).
11. Wu Y-L *et al*. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. *Ann. Oncol*. 26(9), 1883–1889 (2015).
12. Yang J-J *et al*. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. *Br. J. Cancer*. 116(5), 568–574 (2017).
13. Shi YK *et al*. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. *Ann. Oncol*. 28(10), 2443–2450 (2017).
14. Sequist LV *et al*. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 31(27), 3327–3334 (2013).
15. Yang JC-H *et al*. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol*. 16(2), 141–151 (2015).
16. Wu Y-L *et al*. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol*. 15(2), 213–222 (2014).
17. Park K *et al*. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol*. 17(5), 577–589 (2016).
18. Paz-Ares L *et al*. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. *Ann. Oncol*. 28(2), 270–277 (2017).
19. Wu Y-L *et al*. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 18(11), 1454–1466 (2017).
20. Mok TS *et al*. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. *Drugs.* 81(2), 257–266 (2021).
21. Soria J-C *et al*. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N. Engl. J. Med*. 378(2), 113–125 (2018).
22. Ramalingam SS *et al*. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N. Engl. J. Med*. 382(1), 41–50 (2020).